Core Viewpoint - The approval of the clinical trial application for ActRIIA/B antibody JMT206 by the company marks a significant advancement in obesity treatment, contributing to a notable increase in stock price [1] Group 1: Company Developments - The stock price of the company increased by 6.56%, reaching HKD 8.27, with a trading volume of HKD 314 million [1] - The clinical trial application for JMT206 was approved on November 25, aimed at treating obesity [1] Group 2: Product Details - JMT206 is a potent ActRIIA/B antibody with an IC50 in the pM range for blocking Actvin A, GDF8, and GDF11-induced ActRIIA/B activation [1] - The preclinical research data for JMT206 was disclosed at ObesityWeek in November, showing cross-species activity in humans, monkeys, rabbits, rats, and mice [1] - In a three-week treatment on mice, weight gain ranged from 8.12% to 22.12%, with weight gain associated with muscle increase [1] - When combined with semaglutide, JMT206 increased fat loss and reduced muscle loss, with a subcutaneous bioavailability of 65% in monkeys [1]
石药集团再涨超6% ActRIIA/B抗体JMT206注射液临床试验申请获批